Introduction
============

The gastric region is the most frequent site of extra nodal lymphoma ([@b1-ol-0-0-4124]). Gastric lymphoma, which originates from the mucosa-associated lymphoid tissue (MALT), behaves as an indolent disease and has a favorable long-term prognosis with a 10-year survival rate of \>90%. Most cases of gastric MALT lymphoma remain localized within the gastric region for many years ([@b2-ol-0-0-4124]).

Gastric MALT lymphoma is difficult to diagnose due to its non-specific symptoms and various endoscopic findings ([@b3-ol-0-0-4124]). *Helicobacter pylori* (*H. pylori*) infection is associated with gastric MALT lymphoma. Therefore, *H. pylori* eradication (HPE) is a potentially effective therapeutic option in cases of early-stage, low-grade gastric MALT lymphoma. This leads to remission in \>75% of patients ([@b4-ol-0-0-4124]). However, the management strategy for *H. pylori*-negative, lymphoma residuals, or recurrent disease is not well-defined. Treatment guidelines recommend a stage-dependent approach, favoring radiotherapy (RT) for localized and chemotherapy (CT) for advanced stages of the disease ([@b5-ol-0-0-4124]). However, clinicians and patients have to balance the risks and benefits of specific treatments without high-level evidence or long-term survival data. Different prognostic factors for gastric MALT lymphoma have been identified, including neoplasia stage, depth of infiltration in the gastric wall, localization in the stomach, and patient ethnicity ([@b6-ol-0-0-4124]--[@b9-ol-0-0-4124]).

We conducted a retrospective analysis in the patients with gastric MALT lymphoma to analyze the clinical characteristics, prognostic factors and long-term outcomes.

Materials and methods
=====================

### Ethics approval

The Ethics Committee of the Tianjin Medical University Cancer Institute and Hospital approved the current study. Patient records/information were anonymized prior to the analysis. Written informed consent was provided by the participants in order for their clinical records to be used in the current study.

The hospital database was searched for gastric MALT lymphoma diagnosed at the Tianjin Medical University Cancer Institute and Hospital, China, between August 2001 and August 2013. Histopathologic diagnosis of the gastric MALT lymphoma was made according to the World Health Organization classification ([@b10-ol-0-0-4124]). Histology and immunohistochemistry of the original histological samples (biopsy or resection specimens) were investigated, and reviewed by at least three histopathologists. Patients were excluded from the study subjects if: i) they had another malignancy at the time of diagnosis; ii) they were human immunodeﬁciency virus-positive cases; or iii) the follow-up period was \<12 months. Following exclusion of those patients, the remaining 103 patients were included in the current study.

### Staging procedures

The patients were restaged according to the Lugano staging system for gastrointestinal non-Hodgkin\'s lymphoma ([@b11-ol-0-0-4124]). The staging workup included patient history, physical examination, endoscopy, barium meal examination, chest X-ray or computed tomography scan, abdominal ultrasound and computed tomography scan, bone marrow aspiration and biopsy, gastric mucosal biopsies or gastrectomy as well as immunohistochemistry. The *H. pylori* infection status was determined by histologic examination, urea breath test, or both to evaluate the status of *H. pylori* infection following HPE. Routine laboratory tests, including measurement of hemoglobin, serum lactate dehydrogenase (LDH) and β2-microglobulin (β2-MG), were also carried out in all 103 patients. Low hemoglobin was defined as \<120 g/l, high serum LDH as \>245 U/l, and high β2-MG as \>2.2 mg/l.

### Treatment modalities

Of the patients with localized gastric MALT lymphoma, 69 patients associated with *H. pylori*-positive and 4 patients with *H. pylori*-negative underwent HPE therapy. Other treatment modalities, such as RT and CT, were also used for treatment. The HPE regimen included proton pump inhibitors (omeprazole, lansoprazole, or rabeprazole) and a combination of antibiotics (amoxicillin, clarithromycin, and metronidazole). CT included monotherapy or a combination of CT and immunotherapy. RT was performed at a median total dose ranging from 26 to 46 Gy. The response was assessed according to the international workshop for NHL standardized criteria ([@b12-ol-0-0-4124]).

### Statistical analysis

Primary endpoints of the survival analysis were overall survival (OS) and progression-free survival (PFS). OS was measured from the date of diagnosis until the date of death due to any cause, or the date of survivors\' final follow-up. The PFS was calculated from the time of diagnosis to the date of treatment failure, relapse, evidence of disease progression, or death due to any cause. The Kaplan-Meier method was used for survival estimations, and the log-rank test for survival comparisons. Variables that influenced the prognosis (P\<0.05) in the univariate analysis were assessed by a multivariate analysis using the Cox regression model to determine independent prognostic factors for survival. The SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

Patient characteristics are shown in [Table I](#tI-ol-0-0-4124){ref-type="table"}. Patients (n=103) with gastric MALT lymphoma had a median age of 53 years (range: 19--85 years), and included 54 males (M) and 49 females (F) at a ratio of 1:1. The onset of the disease was often insidious and without specific clinical manifestation. None of the patients experienced perforation prior to treatment. Their serum LDH and β2-MG were usually within normal limits. In all 103 patients, the diagnosis was made on the basis of an endoscopic biopsy. Macroscopically, the most commonly involved site was the antrum (60.7%), followed by the corpus (51.6%), and fundus (23.5%). Most patients appeared ulcerative (78.4%). Using the Lugano staging system, 40 patients (39%) had stage I, and 35 patients (35%) were diagnosed with local or distant nodal involvement. There were also patients with stage IIIE (20/103, 19%) and stage IV (8/103, 7%) disease.

### HPE

The *H. pylori* infection rate was 94% (97/103), whereas the infection rate was 100% (28/28) in patients with advanced stages. A total of 73 patients with localized disease, including 69 patients associated with *H. pylori*-positive and 4 patients with *H. pylori*-negative, received HPE as a first-line treatment. *H. pylori* was eradicated in all the positive patients (69/69), although in 17 of these patients, a second-line HPE was required. The symptoms disappeared or were markedly reduced in the majority of patients. The CR was achieved in 54 of the 69 patients (78%) with *H. pylori*-positive and in 2 of the 4 patients (50%) with *H. pylori*-negative. The median time to complete remission (CR) after HPE was 4 months (range: 3--9 months). HPE had a superior trend in the *H. pylori*-positive patients but was not significantly different in the two groups (p=0.194).

### Other treatment modalities

The 16 patients, including 14 patients who failed to achieve CR by HPE and 2 patients associated with *H. pylori*-negative, received RT. The remaining 3 patients who failed to achieve CR by HPE were followed on watch-and-wait strategy due to improved endoscopic features and relief symptoms. The success rate of RT was 100% (16/16). Of note, the 3 patients treated by watch-and-wait strategy, only 1 had disease recurrence by gastric *H. pylori* reinfection and a second remission was obtained following a second-line HPE.

Of the 28 patients with advanced stages, 12 patients received CT or RT combined with HPE and *H. pylori* was eradicated in the 12 patients. CR was achieved in 8 of the 12 patients (67%). The remaining 16 patients received CT or RT. The CR was achieved in 10 of the 16 patients (63%). There was no statistical difference in the two groups (p=0.820).

### Survival analysis

The median follow-up time was 62.9 months (range: 1--226 months). The median PFS was 41.5 months (range: 1--132 months), and the median OS was 59.5 months (range: 2--226 months). The 5-year PFS and OS estimates for the 103 patients were 58 and 69%, respectively ([Fig. 1](#f1-ol-0-0-4124){ref-type="fig"}). The 5-year PFS and OS estimates were compared between patients receiving CT or RT combined with HPE and those receiving CT or RT. We found that the five-year PFS and OS estimates were significantly improved (p\<0.05, [Fig. 2](#f2-ol-0-0-4124){ref-type="fig"}) for patients receiving CT or RT combined with HPE than those receiving CT or RT.

Based on the univariate analysis, the B symptoms, serum LDH \>245 U/l, β2-MG \>2.2 mg/l, advanced stages, PS ≥2 and modified-International Prognostic Index (m-IPI) (≥2) adversely affected PFS and OS ([Table II](#tII-ol-0-0-4124){ref-type="table"}). Advanced stages were significant only for shorter PFS, and m-IPI (≥2) retained its prognostic significance for the shorter OS with multivariate analysis ([Table III](#tIII-ol-0-0-4124){ref-type="table"}).

Discussion
==========

Gastric MALT lymphoma is an indolent disease with a prolonged clinical course that most often involves the stomach ([@b3-ol-0-0-4124]). The clinical presentation is similar to gastric carcinomas and benign ulcers, and commonly includes abdominal pain or discomfort, and with less frequent signs such as bleeding and perforation. The duration of the symptoms prior to diagnosis is variable, ranging from a few weeks to several years. B symptoms are exceedingly rare, and adverse biological prognostic factors such as high serum LDH and β2-MG levels are infrequently elevated. *H. pylori* is linked to the development of gastric MALT lymphoma ([@b12-ol-0-0-4124]), and they occurred frequently in the present study. The clinical characteristics of gastric MALT lymphoma in the present study are similar to those reported in previous studies ([@b3-ol-0-0-4124],[@b13-ol-0-0-4124],[@b14-ol-0-0-4124]).

Identification of the etiologic role of *H. pylori* infection in gastric MALT lymphoma has radically changed the therapeutic approach for such neoplasia. Following successful HPE, lymphoma remission was achieved in 77.5% of 1,408 patients with gastric MALT lymphoma at the early stages with a median time of 5 months ([@b15-ol-0-0-4124]). In the present study, we found that the remission of gastric MALT lymphoma was achieved after HPE in 56 patients (77%) of 73 patients with localized disease. This figure was comparable to the results of several reported large cases ([@b16-ol-0-0-4124]--[@b18-ol-0-0-4124]). Of note, in the present study, 2 patients with *H. pylori*-negative successfully achieved CR by HPE and there were no significant differences in the CR rate following HPE between the *H. pylori*-positive and -negative groups, which is consistent with a previous study ([@b19-ol-0-0-4124]). Eradication therapy may be useful for *H. pylori*-negative gastric MALT lymphoma: first, another infective organism such as *Helicobacter heilmannii*, might be involved in the development of gastric MALT lymphoma ([@b20-ol-0-0-4124]); second, because of very low bacterial counts, conventional examination did not detect the organisms ([@b21-ol-0-0-4124]). Currently, unlike that for *H. pylori*-positive MALT lymphoma, the optimal management of *H. pylori*-negative MALT lymphoma remains controversial. These findings suggest that HPE therapy may be considered as a first-line treatment regardless of *H. pylori* infection status. In addition, there was no difference in 5-year OS between patients who received CT or RT with HPE and those receiving CT or RT. Patients who received CT or RT combined with HPE had an improved 5-year PFS and OS than those who received CT or RT. This result suggests that HPE may improve the prognosis of advanced stages of gastric MALT lymphoma. Since advanced gastric MALT lymphoma is likely a progression from localized to extensive disease, they may still be completely cured by HPE. According to the currently published European Society of Medical Oncology guidelines, HPE should be administered to all gastric MALT lymphomas, independent of the stages and even in *H. pylori*-negative cases ([@b22-ol-0-0-4124]). However, large-scale prospective randomized clinical trials are needed to document any HPE benefits for patients with gastric MALT lymphoma.

There are no accepted prognostic factors for gastric MALT lymphoma thus far. A recent study by Wirth *et al* ([@b23-ol-0-0-4124]) showed that there was a trend to the poorer outcome with increasing age, lymph node involvement and stomach wall thickening. Previous studies ([@b6-ol-0-0-4124],[@b24-ol-0-0-4124]) described the grade of malignancy and stage of the disease as the two major prognostic factors. Translocation t(11;18), the most common genetic aberration in gastric MALT lymphomas is associated with poorer outcome as it strongly predicts the response of gastric MALT lymphoma to HPE ([@b25-ol-0-0-4124]). The IPI has been correlated with relapse, while the utility of IPI is controversial. Previous studies ([@b26-ol-0-0-4124],[@b27-ol-0-0-4124]) have demonstrated that stage m-IPI is an effective predictive factor for patients with gastric lymphoma, where m-IPI was more accurate than the IPI for predicting gastric lymphoma patient survival. In our analysis, stage m-IPI was identified as an independent prognostic factor for OS in the multivariate analysis. Patients in the low-risk group (m-IPI ≤1) had significantly longer survival than the intermediate/high-risk (m-IPI ≥2) patients. Our multivariate analysis revealed that advanced stage of lymphoma was an independent prognostic factor for PFS. Previous findings ([@b27-ol-0-0-4124],[@b28-ol-0-0-4124]) have also shown that the prognosis for gastric lymphoma is influenced by the depth of infiltration and is exacerbated with metastasis to other organs. Ranaldi *et al* ([@b29-ol-0-0-4124]) showed there was no difference in the survival rate between stages I and II gastric lymphoma. However, there was a trend for increasing hazard as the neoplasia progresses from stages II to IIE (p=0.001). We believe that advanced lymphoma stages are crucial for prognostic evaluation, although the exact relationship between disease stage and outcomes remains to be established. Studies identifying other prognostic markers remain to be undertaken.

In conclusion, the results of the present study confirm the indolent course of gastric MALT lymphoma with late relapse and prolonged survival. The patients with advanced stages and m-IPI (≥2), however, tend to have a worse prognosis. As an effective treatment for gastric MALT lymphoma, HPE therapy should be administered to all gastric MALT lymphomas, independently of stage and even in *H. pylori*-negative cases.
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###### 

Characteristics of 103 patients with gastric MALT lymphoma.

  Feature                                              No. (%)
  ---------------------------------------------------- ---------
  Gender                                               
    Female                                             51 (50)
    Male                                               52 (50)
  Age                                                  
    ≤60                                                35 (34)
    \>60                                               38 (66)
  Lugano staging                                       
    I--II2                                             75 (73)
    IIE-IV                                             28 (27)
  Serum LDH level                                      
    Normal                                             78 (76)
    Abnormal                                           25 (24)
  B symptoms                                           
    Present                                            51 (50)
    Absent                                             52 (50)
  β2-microglobulin                                     
    Normal                                             72 (70)
    Abnormal                                           31 (30)
  m-IPI^[a](#tfn2-ol-0-0-4124){ref-type="table-fn"}^   
    0--1                                               78 (76)
    ≥2                                                 15 (15)
    Unknown                                            10 (9)
  Infection with *H. pylori*                           
    Positive                                           97 (94)
    Negative                                           6 (6)
  Tumor mass                                           
    \<5 cm                                             56 (54)
    ≥5 cm                                              34 (33)
    Unknown                                            13 (13)
  Performance status                                   
    \<2                                                72 (70)
    ≥2                                                 15 (15)
    Unknown                                            16 (15)
    Anemia                                             
    Present                                            48 (47)
    Absent                                             55 (53)

Adverse factors for

m-IPI (stage-m-IPI) included age \>60 years, serum LDH \>245 U/l, PS ≥2, advanced stage, ≥1 extranodal site involvement (excluding stomach). *H. pylori, Helicobacter pylori;* MALT, mucosa- associated lymphoid tissue; LDH, lactate dehydrogenase; m-IPI, modified-International Prognostic Index; PS, performance status.

###### 

Univariate analysis of prognostic factors for PFS and OS.

                                OS      PFS              
  ----------------------------- ------- ------- -------- -------
  Age                           3.118   0.077   0.795    0.373
  Gender                        0.030   0.864   0.450    0.502
  B symptoms                    5.025   0.025   10.449   0.001
  Anemia                        1.508   0.208   0.511    0.475
  Serum LDH \>245 U/l           6.213   0.013   7.261    0.007
  β2-microglobulin \>2.2 mg/l   9.604   0.002   8.098    0.004
  Tumor mass ≥10 cm             3.873   0.275   4.215    0.239
  *H. pylori*-positive          2.747   0.253   4.238    0.120
  Advanced stages               4.028   0.045   4.930    0.026
  PS ≥2                         5.998   0.014   74.897   0.000
  m-IPI ≥2                      5.784   0.017   4.389    0.036

PFS, progression-free survival; OS, overall survival; LDH, lactate dehydrogenase; *H. pylori, Helicobacter pylori;* PS, performance status; m-IPI, modified-International Prognostic Index.

###### 

Factors retaining prognostic significance for PFS and OS with multivariate and Cox proportional hazards analysis.

                                OS      PFS                                             
  ----------------------------- ------- --------------- ------- ------- --------------- -------
  B symptoms                    4.982   0.000--0.548    0.246   0.191   0.311--2.172    0.514
  Serum LDH \>245 U/l           4.266   1.216--17.132   0.069   2.029   0.165--3.517    0.917
  β2-microglobulin \>2.2 mg/l   1.564   0.467--31.345   0.211   1.273   0.417--3.218    0.287
  Advanced stages               2.936   0.002--1.524    0.087   1.157   0.924--11.627   0.028
  PS ≥2                         0.620   0.272--21.203   0.431   2.137   0.056--1.087    0.106
  m-IPI ≥2                      6.937   3.721--77.677   0.008   4.682   0.826--11.235   0.076

PFS, progression-free survival; OS, overall survival; CI, confidence interval; LDH, lactate dehydrogenase; PS, performance status; m-IPI, modified-International Prognostic Index.
